Personalised therapeutic vaccines
There is an urgent need for development of a new type of technology to manufacture individualised peptide vaccines for cancer patients in a clinically meaningful time frame.
Personalised vaccines that are patient-specific is one avenue that Maurice Wilkins Centre investigators have expertise in developing and commercialising. This work will draw upon advances made in other Cancer Immunology flagship research programmes, including profiling personalised immune biomarkers and targeted drug delivery to tumour cells. MWC investigators have developed the expertise and equipment to generate tumour-killing T cells primed to target each patient’s tumour cells based on the altered proteins they produce because of their specific mutations. The goal is to develop commercial technologies that are able to produce cancer vaccines quickly and affordably for clinical use.